-- Validating a novel metabolomic diagnostic test for PD (Hyman Schipper, MD, PhD, FRCPC, and Peter Roos, Ph.D., Molecular Biometrics, Montreal, Canada);
-- Finding new ways to target the PD-implicated gene LRRK2 (Vicki Nienaber, Ph.D., Zenobia Therapeutics, San Diego, California);
-- Investigating methods to modulate the new PD target GPR88, a protein receptor believed to play a role in dopaminergic function (Thomas Sager, Ph.D., and Kenneth Thirstrup, Ph.D., H. Lundbeck A/S, Valby, Denmark); and
-- Exploring gene-knockout techniques to protect against oxidative stress implicated in the neuronal loss that characterizes PD (Kenneth Thirstrup, PhD, and Thomas Sager, Ph.D., H. Lundbeck A/S, Valby, Denmark).
Detailed grant abstracts and researchers' bios are available at http://www.michaeljfox.org.
While The Michael J. Fox Foundation has funded industry research teams since its inception, it launched the Therapeutics Development Initiative in 2006 as part of a proactive initiative to capture the attention and imagination of for-profit decision-makers and encourage them to allocate resources to Parkinson's drug development. In 2007, recognizing the increasing sophistication of many university drug development programs, the Foundation added a one-time-only "academic track" to fund non-industry-based teams working toward transformative PD treatments. The Foundation has committed about $24 million in total funding to industry to date. Slightly less than half of that total (over $10 million) has gone to the 20 projects funded through the Therapeutics Development Initiative thus far.
The deadline for pre-proposals under the next $2.5-million,
industry-only funding round of TDI is January 20, 2009. The program will
again seek to support preclinical development of Parkinson's disease
therapies with pot
|SOURCE Michael J. Fox Foundation|
Copyright©2008 PR Newswire.
All rights reserved